Кишечная микробиота и применение пробиотиков с позиции доказательной медицины
Кишечная микробиота и применение пробиотиков с позиции доказательной медицины
Захарова И.Н., Дмитриева Ю.А. Кишечная микробиота и применение пробиотиков с позиции доказательной медицины. Consilium Medicum. Педиатрия (Прил.). 2016; 4: 24–28.
________________________________________________
Zakharova I.N., Dmitrieva Yu.A. The intestinal microbiota and use of probiotics from the position of evidence-based medicine. Consilium Medicum. Pediatrics (Suppl.). 2016; 4: 24–28.
Кишечная микробиота и применение пробиотиков с позиции доказательной медицины
Захарова И.Н., Дмитриева Ю.А. Кишечная микробиота и применение пробиотиков с позиции доказательной медицины. Consilium Medicum. Педиатрия (Прил.). 2016; 4: 24–28.
________________________________________________
Zakharova I.N., Dmitrieva Yu.A. The intestinal microbiota and use of probiotics from the position of evidence-based medicine. Consilium Medicum. Pediatrics (Suppl.). 2016; 4: 24–28.
Результаты научных исследований, проведенных с помощью современных методик, во многом изменили существовавшие представления о составе и роли кишечной микробиоты для организма человека. Активное внедрение молекулярно-генетических технологий позволило идентифицировать более 1 тыс. видов микроорганизмов, населяющих ЖКТ. Процесс становления кишечной микробиоты начинается еще во внутриутробный период, продолжается в течение многих лет и зависит от таких факторов, как способ родоразрешения, характер вскармливания, место родов (на дому, в родильном доме), а также от проводимой антибактериальной терапии, условий проживания и т.д. Нарушение нормальной колонизации кишечника у детей может стать причиной возникновения ряда заболеваний, включая аллергические, функциональные нарушения ЖКТ, инфекционные диареи, воспалительные заболевания кишечника, метаболические нарушения и др. В качестве перспективного направления терапии данных состояний в настоящее время рассматривается применение таргетных пробиотиков с доказанной клинической эффективностью и безопасностью. Одним из наиболее изученных пробиотических штаммов, рекомендуемых к применению в педиатрии, является Lactobacillus reuteri DSM 17938.
The results of research conducted with the help of modern techniques, in many ways changed the existing ideas about the composition and role of the gut microbiota to the human body. Active introduction of molecular genetic techniques allowed the identification of more than 1 thousand. Microbial species inhabiting the gastrointestinal tract. The process of formation of the intestinal microbiota begins in utero, continuing for many years and depends on factors such as the mode of delivery, the nature of feeding, place birth (at home, in a nursing home), as well as from ongoing antibiotic therapy, living conditions, etc. Violation of the normal colonization of the intestines in children can cause a number of diseases, including allergic, functional disorders of the gastrointestinal tract, infectious diarrhea, inflammatory bowel disease, metabolic disorders, and others. As perspective directions of therapy conditions the data is now considered the use of targeted probiotics with proven clinical efficacy and safety. One of the most studied probiotic strains recommended for use in pediatric patients is Lactobacillus reuteri DSM 17938.
1. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59–65.
2. Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174–80.
3. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol 2015; 31 (1): 69–75.
4. Jimenez E, Fernandez L, Marin ML et al. Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr Microbiol 2005; 51: 270–4.
5. Satokari R, Gronroos T, Laitinen K et al. Bifidobacterium and Lactobacillus DNA in the human placenta. Lett Appl Microbiol 2009; 48: 8–12.
6. Grönlund MM, Lehtonen OP, Eerola E et al. Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after Caesarean section delivery. J Pediatr Gastroenterol Nutr 1999; 28: 19–25.
7. Gueimonde M, Laitinen K, Salminen S et al. Breast-milk: a source of bifidobacteria for infant gut development and maturation? Neonatology 2007; 92: 64–6.
8. Jost T, Lacroix C, Braegger C et al. Assessment of bacterial diversity in breastmilk using culture-dependent and culture independent approaches. Br J Nutr 2013; 110: 1253–62.
9. Roger LC, Costabile A, Holland DT et al. Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology 2010; 156: 3329–41.
10. Iacono G, Merolla R, D'Amico D et al. Gastrointestinal symptoms in infancy: a population-based prospective study. Dig Liver Dis 2005; 37 (6): 432–8.
11. Захарова И.Н., Боровик Т.Э., Яцык Г.В. и др. Младенческие кишечные колики: лечить или не лечить? М.: РМАПО, 2013. / Zakharova I.N., Borovik T.E., Iatsyk G.V. i dr. Mladencheskie kishechnye koliki: lechit' ili ne lechit'? M.: RMAPO, 2013. [in Russian]
12. Lehtonen L, Korvenranta H, Eerola J. Intestinal microflora in colicky and noncolicky infants: bacterial cultures and gas-liquid chromatography. J Pediatr Gastroenterol Nutr 1994; 19 (3): 310–4.
13. Savino F, Cordisco L, Tarasco V et al. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr 2009; 98 (10): 1582–8.
14. Savino F, Ceratto S. Advances in Infantile colic and the use of Probiotics. Funct Food Rev 2012; 4 (4): 152–7.
15. Rhoads JM, Fatheree NY, Norori J et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J Pediatr 2009; 155 (6): 823–8.
16. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol 2001; 2: 43–53.
17. Valeur N, Engel P, Carbajal N et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 2004; 70 (2): 1176–81.
18. Rosander A, Connolly E, Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol 2008; 74 (19): 6032–40.
19. Axelson LT, Chung TC, Dobrogosz WJ, Lindgren SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis 1989; 2: 131–6.
20. Chung TC, Axelsson L, Lindgren SE, Dobrogosz WJ. In vitro studies on reuterin synthesis by Lactobacillus reuteri. Microb Ecol Health Dis 1989; 2: 137–44.
21. Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol 2009; 11 (9): 35. DOI: 10.1186/1471-2180-9-3.
22. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol 2012; 302 (6): G608–G617.
23. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010; 299 (5): G1087–G1096.
24. Savino F, Pelle E, Palumeri E. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007; 119: e124–30.
25. Savino F, Cordisco L, Tarasco V et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010; 126 (3): e526–33.
26. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr 2013; 162 (2): 257–62.
27. Coccorullo P, Strisciuglio C, Martinelli M et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo- controlled study. J Pediatr 2010; 157 (4): 598–602.
28. Romano C, Ferrau V, Cavataio F et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014; 50 (10): E68–71.
29. Indrio F, Riezzo G, Raimondi F et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Investig 2011; 41 (4): 417–22.
30. Urbańska M., Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. Eur J Pediatr 2014; 173 (10): 1327–37.
31. Francavilla R, Lionetti E, Castellaneta S et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhea – a double-blind study. Aliment Pharmacol Ther 2012; 36 (4): 363–9.
32. Dinleyici EC, PROBAGE Study Group. Vandenplas Y. Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children. Acta Paediatr 2014; 103 (7): e300–5.
33. Szajewska H, Urbańska M, Chmielewska A et al. Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children. Benef Microbes 2014; 5 (3): 285–93.
34. Szajewska H, Guarino A, Hojsak I et al. Use of Probiotics for Management of Acute Gastroenteritis: A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 2014; 58 (4): 531–9.
35. Gutierrez-Castrellon P, Lopez-Velazquez G, Diaz-Garcia L et al. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 2014; 133: e904.
________________________________________________
1. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59–65.
2. Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174–80.
3. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol 2015; 31 (1): 69–75.
4. Jimenez E, Fernandez L, Marin ML et al. Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr Microbiol 2005; 51: 270–4.
5. Satokari R, Gronroos T, Laitinen K et al. Bifidobacterium and Lactobacillus DNA in the human placenta. Lett Appl Microbiol 2009; 48: 8–12.
6. Grönlund MM, Lehtonen OP, Eerola E et al. Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after Caesarean section delivery. J Pediatr Gastroenterol Nutr 1999; 28: 19–25.
7. Gueimonde M, Laitinen K, Salminen S et al. Breast-milk: a source of bifidobacteria for infant gut development and maturation? Neonatology 2007; 92: 64–6.
8. Jost T, Lacroix C, Braegger C et al. Assessment of bacterial diversity in breastmilk using culture-dependent and culture independent approaches. Br J Nutr 2013; 110: 1253–62.
9. Roger LC, Costabile A, Holland DT et al. Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology 2010; 156: 3329–41.
10. Iacono G, Merolla R, D'Amico D et al. Gastrointestinal symptoms in infancy: a population-based prospective study. Dig Liver Dis 2005; 37 (6): 432–8.
11. Zakharova I.N., Borovik T.E., Iatsyk G.V. i dr. Mladencheskie kishechnye koliki: lechit' ili ne lechit'? M.: RMAPO, 2013. [in Russian]
12. Lehtonen L, Korvenranta H, Eerola J. Intestinal microflora in colicky and noncolicky infants: bacterial cultures and gas-liquid chromatography. J Pediatr Gastroenterol Nutr 1994; 19 (3): 310–4.
13. Savino F, Cordisco L, Tarasco V et al. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr 2009; 98 (10): 1582–8.
14. Savino F, Ceratto S. Advances in Infantile colic and the use of Probiotics. Funct Food Rev 2012; 4 (4): 152–7.
15. Rhoads JM, Fatheree NY, Norori J et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J Pediatr 2009; 155 (6): 823–8.
16. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol 2001; 2: 43–53.
17. Valeur N, Engel P, Carbajal N et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 2004; 70 (2): 1176–81.
18. Rosander A, Connolly E, Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol 2008; 74 (19): 6032–40.
19. Axelson LT, Chung TC, Dobrogosz WJ, Lindgren SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis 1989; 2: 131–6.
20. Chung TC, Axelsson L, Lindgren SE, Dobrogosz WJ. In vitro studies on reuterin synthesis by Lactobacillus reuteri. Microb Ecol Health Dis 1989; 2: 137–44.
21. Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol 2009; 11 (9): 35. DOI: 10.1186/1471-2180-9-3.
22. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol 2012; 302 (6): G608–G617.
23. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010; 299 (5): G1087–G1096.
24. Savino F, Pelle E, Palumeri E. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007; 119: e124–30.
25. Savino F, Cordisco L, Tarasco V et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010; 126 (3): e526–33.
26. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr 2013; 162 (2): 257–62.
27. Coccorullo P, Strisciuglio C, Martinelli M et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo- controlled study. J Pediatr 2010; 157 (4): 598–602.
28. Romano C, Ferrau V, Cavataio F et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014; 50 (10): E68–71.
29. Indrio F, Riezzo G, Raimondi F et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Investig 2011; 41 (4): 417–22.
30. Urbańska M., Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. Eur J Pediatr 2014; 173 (10): 1327–37.
31. Francavilla R, Lionetti E, Castellaneta S et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhea – a double-blind study. Aliment Pharmacol Ther 2012; 36 (4): 363–9.
32. Dinleyici EC, PROBAGE Study Group. Vandenplas Y. Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children. Acta Paediatr 2014; 103 (7): e300–5.
33. Szajewska H, Urbańska M, Chmielewska A et al. Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children. Benef Microbes 2014; 5 (3): 285–93.
34. Szajewska H, Guarino A, Hojsak I et al. Use of Probiotics for Management of Acute Gastroenteritis: A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 2014; 58 (4): 531–9.
35. Gutierrez-Castrellon P, Lopez-Velazquez G, Diaz-Garcia L et al. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 2014; 133: e904.
Авторы
И.Н.Захарова*, Ю.А.Дмитриева
ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*zakharova-rmapo@yandex.ru
________________________________________________
I.N.Zakharova*, Yu.A.Dmitrieva
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*zakharova-rmapo@yandex.ru